BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 172 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $37,701 | +1.2% | 5,325 | +0.6% | 0.00% | – |
| Q2 2023 | $37,249 | +232706.2% | 5,291 | +175.6% | 0.00% | – |
| Q1 2023 | $16 | -78.1% | 1,920 | -69.8% | 0.00% | -100.0% |
| Q4 2022 | $73 | -99.9% | 6,350 | +0.2% | 0.00% | 0.0% |
| Q3 2022 | $85,000 | +28.8% | 6,339 | +2.1% | 0.00% | 0.0% |
| Q2 2022 | $66,000 | -34.7% | 6,210 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $101,000 | -5.6% | 6,210 | -10.5% | 0.00% | 0.0% |
| Q4 2021 | $107,000 | -35.2% | 6,940 | -39.7% | 0.00% | 0.0% |
| Q3 2021 | $165,000 | -9.3% | 11,500 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $182,000 | +50.4% | 11,500 | -3.6% | 0.00% | 0.0% |
| Q1 2021 | $121,000 | +450.0% | 11,925 | +307.7% | 0.00% | – |
| Q4 2020 | $22,000 | +214.3% | 2,925 | +41.0% | 0.00% | – |
| Q3 2020 | $7,000 | -30.0% | 2,075 | 0.0% | 0.00% | – |
| Q2 2020 | $10,000 | +150.0% | 2,075 | +5.3% | 0.00% | – |
| Q1 2020 | $4,000 | -50.0% | 1,970 | +97.0% | 0.00% | – |
| Q1 2017 | $8,000 | +14.3% | 1,000 | -61.5% | 0.00% | – |
| Q1 2016 | $7,000 | – | 2,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
| Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
| Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
| Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
| AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
| TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
| Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
| DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
| Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |